Drug Trial Radar · NCT02606630
[11C]-PBR28 Positron Emission Tomography Study to Evaluate the Effect of ABT 555 in Subjects With Relapsing Forms of Multiple Sclerosis
Last checked: Nov 19, 2026Latest source record: Feb 8, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
4
Actual
Start
Oct 2015
Primary completion
Dec 2015
Study completion Dec 2015
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Nov 17, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This open-label positron emission tomography (PET) study is designed to determine the effect of ABT-555 on translocator protein expression level in participants with relapsing forms of multiple sclerosis.
Conditions
- Multiple Sclerosis
Interventions
ABT-555Drug
ABT-555 will be administered on Visit 4 in Part 2 only
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in translocator protein expressionTime frame: Day 0 and 109 days
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Site Reference ID/Investigator# 141463
London, United Kingdom
Site Reference ID/Investigator# 141461
Whitechapel, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.